AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

Conditions:   Preclinical Alzheimer's Disease;   Early Alzheimer's Disease Interventions:   Drug: BAN2401;   Drug: Placebo Sponsors:   Eisai Inc.;   Alzheimer’s Clinical Trial Consortium (ACTC);   Biogen;   National Institute on Aging (NIA) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alzheimer's | Research | Study